Safety profile of cariprazine: Post hoc analysis of safety parameters of pooled cariprazine schizophrenia studies

被引：1
|
作者：
Szatmari, B. [1 ]
Barabassy, A. [1 ]
Laszlovszky, I. [1 ]
Harsanyi, J. [1 ]
Acsai, K. [1 ]
Burjan, A. [1 ]
Sebe, B. [1 ]
Earley, W. [2 ]
Patel, M. [2 ]
Nemeth, G. [1 ]
机构：
[1] Gedeon Richter Plc, Med Div, Budapest, Hungary
[2] Allergan Pharmaceut Inc, Madison, NJ USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷
关键词：
D O I：
10.1016/j.euroneuro.2018.11.635
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.618
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [31] Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data
    Nasrallah, H. A.
    Cutler, A. J.
    Wang, Y.
    Lu, K.
    Nagy, K.
    Laszlovszky, I.
    Durgam, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S536 - S536
  • [32] Safety and tolerability of cariprazine in long-term treatment of schizophrenia: Integrated summary of safety data
    Durgam, S.
    Nasrallah, H. A.
    Nasrallah, Henry A.
    Cutler, A.
    Wang, Y.
    Lu, K.
    Nagy, K.
    Laszlovszky, I.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 68 - 68
  • [33] The Effect of Cariprazine on Hositlity Associated With Schizophrenia: Post Hoc Analysis From 3 Randomized Controlled Trials
    Citrome, Leslie
    Durgam, Suresh
    Lu, Kaifeng
    Ferguson, Paul
    Laszlovszky, Istvan
    JOURNAL OF CLINICAL PSYCHIATRY, 2016, 77 (01) : 109 - 115
  • [34] Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
    Patel, Mehul
    Jain, Rakesh
    Tohen, Mauricio
    Maletic, Vladimir
    Earley, Willie R.
    Yatham, Lakshmi N.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (02) : 76 - 83
  • [35] Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis
    Jain, Rakesh
    Mcintyre, Roger S.
    Cutler, Andrew J.
    Earley, Willie R.
    Nguyen, Huy-Binh
    Adams, Julie L.
    Yatham, Lakshmi N.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2024, 39 (02) : 82 - 92
  • [36] Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole
    Barabassy, A.
    Szatmari, B.
    Laszlovszky, I.
    Harsanyi, J.
    Acsai, K.
    Sebe, B.
    Earley, W.
    Patel, M.
    Nemeth, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S417 - S418
  • [37] Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia
    Riccobene, Todd
    Riesenberg, Robert
    Yeung, Paul P.
    Earley, Willie R.
    Hankinson, Arlene L.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (08) : 434 - 443
  • [38] Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
    István Laszlovszky
    Ágota Barabássy
    György Németh
    Advances in Therapy, 2021, 38 : 3652 - 3673
  • [39] Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
    Laszlovszky, Istvan
    Barabassy, Agota
    Nemeth, Gyorgy
    ADVANCES IN THERAPY, 2021, 38 (07) : 3652 - 3673
  • [40] Pooled analysis of the safety and tolerability profile of aripiprazole in schizophrenia
    Kostic, D
    McQuade, RD
    Saha, AR
    Kaplita, SB
    Archibald, DG
    Iwamoto, T
    Stock, E
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 339 - 339
12345